IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity - PubMed (original) (raw)
. 2001 Apr 26;410(6832):1107-11.
doi: 10.1038/35074122.
Affiliations
- PMID: 11323675
- DOI: 10.1038/35074122
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al. Nature. 2001.
Abstract
Lymphocytes were originally thought to form the basis of a 'cancer immunosurveillance' process that protects immunocompetent hosts against primary tumour development, but this idea was largely abandoned when no differences in primary tumour development were found between athymic nude mice and syngeneic wild-type mice. However, subsequent observations that nude mice do not completely lack functional T cells and that two components of the immune system-IFNgamma and perforin-help to prevent tumour formation in mice have led to renewed interest in a tumour-suppressor role for the immune response. Here we show that lymphocytes and IFNgamma collaborate to protect against development of carcinogen-induced sarcomas and spontaneous epithelial carcinomas and also to select for tumour cells with reduced immunogenicity. The immune response thus functions as an effective extrinsic tumour-suppressor system. However, this process also leads to the immunoselection of tumour cells that are more capable of surviving in an immunocompetent host, which explains the apparent paradox of tumour formation in immunologically intact individuals.
Similar articles
- Adaptive immunity maintains occult cancer in an equilibrium state.
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Koebel CM, et al. Nature. 2007 Dec 6;450(7171):903-7. doi: 10.1038/nature06309. Epub 2007 Nov 18. Nature. 2007. PMID: 18026089 - MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice.
Engel AM, Svane IM, Rygaard J, Werdelin O. Engel AM, et al. Scand J Immunol. 1997 May;45(5):463-70. doi: 10.1046/j.1365-3083.1997.d01-419.x. Scand J Immunol. 1997. PMID: 9160088 - Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1.
Lou Y, Seipp RP, Cai B, Chen SS, Vitalis TZ, Choi KB, Jeffries AP, Gopaul RS, Li XL, Seliger B, Pearson TW, Jefferies WA. Lou Y, et al. Vaccine. 2007 Mar 8;25(12):2331-9. doi: 10.1016/j.vaccine.2006.11.064. Epub 2006 Dec 12. Vaccine. 2007. PMID: 17229499 - Interferon-gamma and cancer immunoediting.
Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. Dunn GP, et al. Immunol Res. 2005;32(1-3):231-45. doi: 10.1385/ir:32:1-3:231. Immunol Res. 2005. PMID: 16106075 Review.
Cited by
- The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy.
Oleksiewicz U, Kuciak M, Jaworska A, Adamczak D, Bisok A, Mierzejewska J, Sadowska J, Czerwinska P, Mackiewicz AA. Oleksiewicz U, et al. Int J Mol Sci. 2024 Oct 25;25(21):11466. doi: 10.3390/ijms252111466. Int J Mol Sci. 2024. PMID: 39519018 Free PMC article. Review. - TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways.
Zhang QB, Wang H, Xu F, Song Y, Jiang RD, Li Q, Liu EY. Zhang QB, et al. Sci Rep. 2024 Nov 2;14(1):26422. doi: 10.1038/s41598-024-78316-3. Sci Rep. 2024. PMID: 39488569 Free PMC article. - Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity.
Li S, Chen K, Sun Z, Chen M, Pi W, Zhou S, Yang H. Li S, et al. Expert Rev Mol Med. 2024 Oct 23;26:e30. doi: 10.1017/erm.2024.27. Expert Rev Mol Med. 2024. PMID: 39438247 Free PMC article. Review. - Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases.
de Arruda Camargo GC, Oliveira G, Santos BNS, Roberto IM, Ávila M, de Souza BR, Alonso JCC, Durán N, Fávaro WJ. de Arruda Camargo GC, et al. Med Oncol. 2024 Oct 15;41(11):287. doi: 10.1007/s12032-024-02533-z. Med Oncol. 2024. PMID: 39404781 - IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.
Sari G, Dhatchinamoorthy K, Orellano-Ariza L, Ferreira LM, Brehm MA, Rock K. Sari G, et al. J Exp Clin Cancer Res. 2024 Oct 2;43(1):276. doi: 10.1186/s13046-024-03187-5. J Exp Clin Cancer Res. 2024. PMID: 39354629 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials